|
FR2697752B1
(fr)
|
1992-11-10 |
1995-04-14 |
Rhone Poulenc Rorer Sa |
Compositions antitumorales contenant des dérivés du taxane.
|
|
US6214388B1
(en)
*
|
1994-11-09 |
2001-04-10 |
The Regents Of The University Of California |
Immunoliposomes that optimize internalization into target cells
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
US7371376B1
(en)
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
|
US6210707B1
(en)
*
|
1996-11-12 |
2001-04-03 |
The Regents Of The University Of California |
Methods of forming protein-linked lipidic microparticles, and compositions thereof
|
|
KR19990029749A
(ko)
*
|
1997-09-17 |
1999-04-26 |
미우라 아끼라 |
2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체
|
|
ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
|
US6410328B1
(en)
*
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
|
PT937456E
(pt)
*
|
1998-02-23 |
2004-10-29 |
Cilag Ag Int |
Dispersao lipossomal de eritropoietina
|
|
US7244826B1
(en)
|
1998-04-24 |
2007-07-17 |
The Regents Of The University Of California |
Internalizing ERB2 antibodies
|
|
AU1678900A
(en)
*
|
1998-08-11 |
2000-03-06 |
All India Institute Of Medical Sciences |
A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
|
|
WO2000020031A1
(en)
*
|
1998-10-02 |
2000-04-13 |
Windy Hill Technology, Inc. |
Methods for identification, diagnosis, and treatment of breast cancer
|
|
US20030049262A1
(en)
*
|
1998-10-02 |
2003-03-13 |
Susan Love |
Methods for identification, diagnosis, and treatment of breast cancer
|
|
AU3191100A
(en)
*
|
1999-03-17 |
2000-10-04 |
Mitsubishi Chemical Corporation |
Ligand-bonded complex
|
|
US6333348B1
(en)
*
|
1999-04-09 |
2001-12-25 |
Aventis Pharma S.A. |
Use of docetaxel for treating cancers
|
|
EP1645291A1
(en)
|
1999-05-07 |
2006-04-12 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
|
|
NZ516830A
(en)
|
1999-06-25 |
2004-07-30 |
Genentech Inc |
Humanized anti-ErbB2 antibodies conjugated with a cytotoxic or chemotherapeutic agent for treating cancer
|
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
GB9915074D0
(en)
*
|
1999-06-28 |
1999-08-25 |
Cortecs Plc |
Ligand-binding composition
|
|
HU231064B1
(hu)
|
1999-08-27 |
2020-03-30 |
Genentech, Inc. |
Anti-ErbB2 antitestek adagolási sémái és alkalmazásuk rákos betegségek kezelésére
|
|
AU2136501A
(en)
*
|
1999-12-10 |
2001-06-18 |
Celator Technologies Inc. |
Lipid carrier compositions with protected surface reactive functions
|
|
US20040009229A1
(en)
*
|
2000-01-05 |
2004-01-15 |
Unger Evan Charles |
Stabilized nanoparticle formulations of camptotheca derivatives
|
|
US20020004587A1
(en)
|
2000-04-11 |
2002-01-10 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
|
EP1280923A2
(en)
*
|
2000-04-28 |
2003-02-05 |
Millennium Pharmaceuticals, Inc. |
14094, a human trypsin family member and uses thereof
|
|
CN1447696A
(zh)
|
2000-05-19 |
2003-10-08 |
杰南技术公司 |
用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
|
|
JP2004512262A
(ja)
|
2000-06-20 |
2004-04-22 |
アイデック ファーマスーティカルズ コーポレイション |
非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
|
|
MXPA03004095A
(es)
|
2000-11-09 |
2004-09-10 |
Neopharm Inc |
Complejos de sn-38 con lipidos y sus metodos de uso.
|
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
HUP0101480A2
(hu)
*
|
2001-04-11 |
2004-01-28 |
István Horváth |
Eljárás koleszterinből nyerhető baktérium-méretű partikulák előállítására
|
|
AU2002305452A1
(en)
*
|
2001-05-08 |
2002-11-18 |
Emory University |
Regulating immine responses using dendritic cells
|
|
WO2003030864A1
(en)
*
|
2001-05-29 |
2003-04-17 |
Neopharm, Inc. |
Liposomal formulation of irinotecan
|
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
|
AU2002318371B2
(en)
|
2001-06-20 |
2006-06-15 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
|
WO2003024392A2
(en)
|
2001-09-18 |
2003-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US20030228319A1
(en)
|
2002-04-16 |
2003-12-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
NZ533933A
(en)
|
2002-01-02 |
2008-06-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of glioma tumor
|
|
EP1487273B1
(en)
|
2002-02-13 |
2009-01-21 |
Immunology Laboratories, Inc. |
Compositions and methods for treatment of microbial infections
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
KR100470535B1
(ko)
*
|
2002-06-27 |
2005-02-22 |
재단법인서울대학교산학협력재단 |
유피에이 항체 부착 이뮤노리포좀
|
|
NZ537660A
(en)
|
2002-07-15 |
2008-12-24 |
Genentech Inc |
Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
|
|
AU2003262650B2
(en)
|
2002-08-14 |
2009-10-29 |
Macrogenics, Inc. |
FcgammaRIIB-specific antibodies and methods of use thereof
|
|
WO2004035032A2
(en)
*
|
2002-08-20 |
2004-04-29 |
Neopharm, Inc. |
Pharmaceutical formulations of camptothecine derivatives
|
|
US20060030578A1
(en)
*
|
2002-08-20 |
2006-02-09 |
Neopharm, Inc. |
Pharmaceutically active lipid based formulation of irinotecan
|
|
CA2832136C
(en)
|
2002-09-27 |
2015-11-17 |
Xencor |
Optimized fc variants and methods for their generation
|
|
MXPA05006579A
(es)
*
|
2002-12-19 |
2005-12-14 |
Johnson & Johnson |
Metodo para tratar el crecimiento de tejido angiogenico.
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
EP2062916A3
(en)
|
2003-04-09 |
2009-08-19 |
Genentech, Inc. |
Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
|
|
EP2784084B2
(en)
|
2003-07-08 |
2023-10-04 |
Novartis Pharma AG |
Antagonist antibodies to IL-17A/F heterologous polypeptides
|
|
US20070148170A1
(en)
|
2005-10-03 |
2007-06-28 |
Desjarlais John R |
Fc Variants With Optimized Fc Receptor Binding Properties
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
WO2005037858A2
(en)
*
|
2003-10-16 |
2005-04-28 |
University Of Massachusetts |
Template-directed assembly of receptor signaling complexes
|
|
WO2005040163A1
(en)
|
2003-10-28 |
2005-05-06 |
Dr. Reddy's Laboratories Ltd |
Heterocyclic compounds that block the effects of advanced glycation end products (age)
|
|
US20050147664A1
(en)
*
|
2003-11-13 |
2005-07-07 |
Elan Pharma International Ltd. |
Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
|
|
NZ596984A
(en)
|
2003-11-17 |
2013-10-25 |
Genentech Inc |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
WO2005080432A2
(en)
|
2004-02-19 |
2005-09-01 |
Genentech, Inc. |
Cdr-repaired antibodies
|
|
WO2006074418A2
(en)
|
2005-01-07 |
2006-07-13 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
|
RU2424792C2
(ru)
|
2004-05-03 |
2011-07-27 |
Хермес Байесайенсиз, Инк. |
Липосомы, используемые для доставки лекарственных средств
|
|
KR20070029733A
(ko)
|
2004-06-04 |
2007-03-14 |
제넨테크, 인크. |
다발성 경화증의 치료 방법
|
|
JP4433918B2
(ja)
*
|
2004-07-15 |
2010-03-17 |
コニカミノルタエムジー株式会社 |
画像形成方法
|
|
KR100863776B1
(ko)
|
2004-07-15 |
2008-10-16 |
젠코어 인코포레이티드 |
최적화된 Ｆｃ 변이체
|
|
WO2006014928A1
(en)
|
2004-07-26 |
2006-02-09 |
Genentech, Inc. |
Methods and compositions for modulating hepatocyte growth factor activation
|
|
JP2008515929A
(ja)
*
|
2004-10-08 |
2008-05-15 |
アルザ コーポレイション |
脂質連結部分を予備形成した脂質集合体にマイクロ波を使用して挿入する方法
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
|
EP1807051A2
(en)
*
|
2004-11-05 |
2007-07-18 |
Inex Pharmaceuticals Corporation |
Compositions and methods for stabilizing liposomal camptothecin formulations
|
|
KR100651728B1
(ko)
*
|
2004-11-10 |
2006-12-06 |
한국전자통신연구원 |
정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
|
|
BRPI0517837A
(pt)
|
2004-11-12 |
2008-10-21 |
Xencor Inc |
variantes fc com ligação alterada a fcrn
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
CN101437551A
(zh)
*
|
2004-11-19 |
2009-05-20 |
皇家飞利浦电子股份有限公司 |
用于分子成像的超声造影剂
|
|
TWI441646B
(zh)
|
2005-01-21 |
2014-06-21 |
Genentech Inc |
帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
|
|
BRPI0606557A2
(pt)
*
|
2005-02-09 |
2009-06-30 |
Genentech Inc |
método de inibição do abrigo de her2, método de redução do nìvel em soro de domìnio extracelular (ecd) de her2 em mamìferos, métodos de tratamento de cáncer em mamìferos, método de redução do nìvel de p95 her2 em célula e método de diagnóstico
|
|
MY152164A
(en)
|
2005-02-23 |
2014-08-15 |
Genentech Inc |
Extending time to disease progression or survival in cancer patients
|
|
US20060204505A1
(en)
*
|
2005-03-08 |
2006-09-14 |
Sliwkowski Mark X |
Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
|
|
CN101175769A
(zh)
|
2005-03-10 |
2008-05-07 |
健泰科生物技术公司 |
用于调控血管完整性的方法和组合物
|
|
KR20080002995A
(ko)
*
|
2005-04-22 |
2008-01-04 |
알자 코포레이션 |
Ｈｅｒ２ 세포 수용체를 표적하는 이뮤노리포좀 조성물
|
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
|
|
EP2186402A1
(en)
|
2005-06-06 |
2010-05-19 |
Genentech, Inc. |
Knock-out animal models for novel genes and methods of use
|
|
TW200726485A
(en)
*
|
2005-07-01 |
2007-07-16 |
Alza Corp |
Liposomal delivery vehicle for hydrophobic drugs
|
|
WO2007008943A2
(en)
|
2005-07-08 |
2007-01-18 |
Xencor, Inc. |
Optimized anti-ep-cam antibodies
|
|
US20070055200A1
(en)
*
|
2005-08-10 |
2007-03-08 |
Gilbert Scott J |
Needle-free jet injection drug delivery device
|
|
AU2006280321A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
|
ES2272178B1
(es)
*
|
2005-09-19 |
2008-03-16 |
Daniel Serrano Gil |
Una composicion para ser administrada a un mamifero o a un ser humano.
|
|
US20090155272A1
(en)
*
|
2005-09-30 |
2009-06-18 |
Muschler John L |
Targeted pharmaceuticals and ligands
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
US20070172520A1
(en)
*
|
2005-11-18 |
2007-07-26 |
University Of South Florida |
Immunotargeting of Nonionic Surfactant Vesicles
|
|
JP2009516514A
(ja)
|
2005-11-21 |
2009-04-23 |
ジェネンテック・インコーポレーテッド |
新規遺伝子破壊、それらに関する組成物および方法
|
|
CA2633742A1
(en)
*
|
2005-12-22 |
2007-06-28 |
Domantis Limited |
Composition
|
|
US20080311107A1
(en)
|
2006-02-17 |
2008-12-18 |
Genetech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
|
EP2004221A2
(en)
|
2006-03-23 |
2008-12-24 |
Novartis Pharma AG |
Anti-tumor cell antigen antibody therapeutics
|
|
AU2007243946B2
(en)
|
2006-04-05 |
2012-11-29 |
Curis, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
|
JP2009536022A
(ja)
|
2006-04-19 |
2009-10-08 |
ジェネンテック・インコーポレーテッド |
新規の遺伝子破壊、それに関連する組成物および方法
|
|
WO2007133801A2
(en)
*
|
2006-05-15 |
2007-11-22 |
Dmitri B Kirpotin |
Magnetic microparticles comprising organic substances
|
|
US20080014205A1
(en)
|
2006-05-15 |
2008-01-17 |
Lawrence Horowitz |
Neutralizing Antibodies to Influenza Viruses
|
|
HUE030269T2
(en)
|
2006-06-26 |
2017-04-28 |
Macrogenics Inc |
FC RIIB-specific antibodies and methods for their use
|
|
WO2008002656A2
(en)
*
|
2006-06-28 |
2008-01-03 |
P.A. Technologies Llc |
Methods and materials for in vitro analysis and/or use of membrane-associated proteins, portions thereof or variants thereof
|
|
EP2046809B1
(en)
|
2006-07-19 |
2016-12-07 |
The Trustees Of The University Of Pennsylvania |
Wsx-1/il-27 as a target for anti-inflammatory responses
|
|
WO2008013918A2
(en)
|
2006-07-26 |
2008-01-31 |
Myelin Repair Foundation, Inc. |
Cell cycle regulation and differentiation
|
|
AU2007284651B2
(en)
|
2006-08-09 |
2014-03-20 |
Institute For Systems Biology |
Organ-specific proteins and methods of their use
|
|
PT2059536E
(pt)
|
2006-08-14 |
2014-04-14 |
Xencor Inc |
Anticorpos otimizados que visam cd19
|
|
US20100292090A1
(en)
|
2006-08-25 |
2010-11-18 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
|
US8444971B2
(en)
|
2006-11-27 |
2013-05-21 |
Diadexus, Inc. |
OVR110 antibody compositions and methods of use
|
|
CN101209243B
(zh)
*
|
2006-12-29 |
2010-12-08 |
石药集团中奇制药技术（石家庄）有限公司 |
一种脂质体药物及其制备方法
|
|
SI2132573T1
(sl)
|
2007-03-02 |
2014-07-31 |
Genentech, Inc. |
Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
|
|
US8367052B2
(en)
|
2007-03-26 |
2013-02-05 |
General Regeneratives Holdings Inc. |
Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies
|
|
CA2693053C
(en)
|
2007-05-30 |
2021-01-05 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
|
EP2592156B1
(en)
|
2007-06-08 |
2016-04-20 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
US9551033B2
(en)
*
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
CL2008002083A1
(es)
|
2007-07-16 |
2008-11-21 |
Genentech Inc |
Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
|
|
SI2474557T1
(sl)
|
2007-07-16 |
2014-12-31 |
Genentech, Inc. |
Protiteles proti CD79b in imunokonjugati in postopki za uporabo
|
|
CN101820913A
(zh)
*
|
2007-08-09 |
2010-09-01 |
第一三共株式会社 |
在表达含死亡结构域的受体的细胞中诱导细胞凋亡的免疫脂质体
|
|
RU2525133C2
(ru)
|
2007-08-30 |
2014-08-10 |
Дайити Санкио Компани, Лимитед |
Антитело к epha2
|
|
ES2395784T3
(es)
|
2007-11-12 |
2013-02-15 |
Theraclone Sciences, Inc. |
Composiciones y métodos para la terapia y diagnosis de la influenza
|
|
WO2010135521A2
(en)
|
2009-05-20 |
2010-11-25 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
DK2808343T3
(da)
|
2007-12-26 |
2019-08-19 |
Xencor Inc |
Fc-varianter med ændret binding til FcRn
|
|
AR070141A1
(es)
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
RS54883B1
(sr)
|
2008-01-31 |
2016-10-31 |
Genentech Inc |
Anti-cd79b antitela i imunokonjugati i metode upotrebe
|
|
JP5544309B2
(ja)
|
2008-03-10 |
2014-07-09 |
セラクローン サイエンシーズ， インコーポレイテッド |
サイトメガロウイルス感染の治療および診断のための組成物および方法
|
|
CA2719201A1
(en)
|
2008-03-28 |
2009-10-01 |
Sea Lane Biotechnologies, Llc. |
Neutralizing molecules to viral antigens
|
|
US20100255508A1
(en)
|
2008-05-16 |
2010-10-07 |
Thomas Richard Gelzleichter |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
|
ITMI20081052A1
(it)
*
|
2008-06-10 |
2009-12-11 |
Univ Milano Bicocca |
Liposomi in grado di legare efficacemente il peptide beta-amiloide
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
KR101647334B1
(ko)
*
|
2008-07-10 |
2016-08-10 |
세리나 쎄라퓨틱스, 인코포레이티드 |
불활성 말단기를 가진 폴리옥사졸린, 보호된 개시기로부터 제조된 폴리옥사졸린 및 그와 관련된 화합물
|
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
US20120027843A1
(en)
*
|
2009-02-04 |
2012-02-02 |
Tetsuo Minamino |
Hb-egf bound protein complex
|
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
|
JP5624114B2
(ja)
|
2009-03-20 |
2014-11-12 |
ジェネンテック， インコーポレイテッド |
抗ｈｅｒ抗体
|
|
SG174891A1
(en)
|
2009-04-01 |
2011-11-28 |
Genentech Inc |
Treatment of insulin-resistant disorders
|
|
MX2011010264A
(es)
|
2009-04-01 |
2011-10-11 |
Genentech Inc |
Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.
|
|
CN102459340A
(zh)
|
2009-04-23 |
2012-05-16 |
特罗科隆科学有限公司 |
粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
|
|
CN102421448A
(zh)
|
2009-05-29 |
2012-04-18 |
霍夫曼-拉罗奇有限公司 |
Her2信号传导调控剂在表达her2的胃癌患者中
|
|
MX2012000129A
(es)
|
2009-06-26 |
2012-02-01 |
Sea Lane Biotechnologies Llc |
Expresion de las cadenas ligeras sustitutas.
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
EP2490718B1
(en)
|
2009-10-22 |
2016-01-13 |
F.Hoffmann-La Roche Ag |
Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
|
|
BR112012012750A2
(pt)
|
2009-11-30 |
2020-08-11 |
Genentech Inc |
anticorpo isolado, célula, ácido nucleíco isolado e método
|
|
EP2509997B1
(en)
|
2009-12-07 |
2017-08-30 |
i2 Pharmaceuticals, Inc. |
Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
|
|
ES2573642T3
(es)
|
2009-12-23 |
2016-06-09 |
Synimmune Gmbh |
Anticuerpos anti-FLT3 y métodos de usar los mismos
|
|
ES2701626T3
(es)
|
2009-12-28 |
2019-02-25 |
Oncotherapy Science Inc |
Anticuerpos anti-CDH3 y sus usos
|
|
WO2011091154A2
(en)
*
|
2010-01-21 |
2011-07-28 |
The Regents Of The University Of California |
Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
|
|
WO2011089211A1
(en)
|
2010-01-22 |
2011-07-28 |
Synimmune Gmbh |
Anti-cd133 antibodies and methods of using the same
|
|
RU2587619C2
(ru)
|
2010-02-18 |
2016-06-20 |
Дженентек, Инк. |
Антагонисты неурегулина и применение их в лечении злокачественного новообразования
|
|
AU2011221226A1
(en)
|
2010-02-23 |
2012-08-16 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
WO2011120134A1
(en)
|
2010-03-29 |
2011-10-06 |
Zymeworks, Inc. |
Antibodies with enhanced or suppressed effector function
|
|
RU2636461C2
(ru)
|
2010-05-03 |
2017-11-23 |
Дженентек, Инк. |
Композиции и способы для диагностики и лечения опухоли
|
|
KR20130060223A
(ko)
|
2010-05-04 |
2013-06-07 |
메리맥 파마슈티컬즈, 인크. |
상피세포 성장인자 수용체(ｅｇｆｒ)에 대한 항체 및 이의 용도
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
EP2603237A4
(en)
|
2010-08-12 |
2014-05-21 |
Theraclone Sciences Inc |
ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
|
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
|
PL3556396T3
(pl)
|
2010-08-31 |
2022-09-12 |
Theraclone Sciences, Inc. |
Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)
|
|
WO2012030842A2
(en)
|
2010-09-03 |
2012-03-08 |
Academia Sinica |
Anti-c-met antibody and methods of use thereof
|
|
AR083546A1
(es)
|
2010-10-25 |
2013-03-06 |
Genentech Inc |
Tratamiento de inflamacion gastrointestinal, soriasis y asma
|
|
US20140199682A1
(en)
|
2010-11-17 |
2014-07-17 |
Sea Lane Biotechnologies, Llc |
Influenza neutralizing agents
|
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
|
EP2648738A2
(en)
|
2010-12-06 |
2013-10-16 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
|
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
EP2675478A4
(en)
|
2011-02-14 |
2015-06-10 |
Theraclone Sciences Inc |
COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF GRIP
|
|
CA2827118A1
(en)
|
2011-02-15 |
2012-08-23 |
Merrimack Pharmaceuticals, Inc. |
Compositions and methods for delivering nucleic acid to a cell
|
|
KR20140012131A
(ko)
|
2011-03-15 |
2014-01-29 |
테라클론 사이언시스, 아이엔씨. |
인플루엔자의 치료 및 진단을 위한 조성물 및 방법
|
|
AR085826A1
(es)
|
2011-03-31 |
2013-10-30 |
Genentech Inc |
METODOS DE ADMINISTRACION DE ANTAGONISTAS DE INTEGRINA b7
|
|
KR101589135B1
(ko)
|
2011-04-20 |
2016-01-29 |
주식회사 셀앤바이오 |
인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
|
|
MX338353B
(es)
|
2011-04-20 |
2016-04-13 |
Medimmune Llc |
Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
|
|
US8691231B2
(en)
|
2011-06-03 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
|
|
WO2013003652A1
(en)
|
2011-06-28 |
2013-01-03 |
Sea Lane Biotechnologies, Llc |
Multispecific stacked variable domain binding proteins
|
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
|
JP6120848B2
(ja)
|
2011-08-15 |
2017-04-26 |
メディミューン，エルエルシー |
抗ｂ７−ｈ４抗体およびその使用
|
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
|
EP2758438A1
(en)
|
2011-09-23 |
2014-07-30 |
Amgen Research (Munich) GmbH |
Bispecific binding molecules for 5t4 and cd3
|
|
WO2013063229A1
(en)
|
2011-10-25 |
2013-05-02 |
The Regents Of The University Of Michigan |
Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
|
|
EP2776051A4
(en)
|
2011-10-28 |
2015-06-17 |
Hoffmann La Roche |
THERAPEUTIC COMBINATIONS AND METHOD FOR THE TREATMENT OF MELANOMA
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
CA2857114A1
(en)
|
2011-11-30 |
2013-06-06 |
Genentech, Inc. |
Erbb3 mutations in cancer
|
|
US9376715B2
(en)
|
2011-12-09 |
2016-06-28 |
Roche Molecular Systems, Inc |
Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
|
|
WO2013090293A1
(en)
|
2011-12-15 |
2013-06-20 |
The University Of Chicago |
Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
|
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
|
CN104203216A
(zh)
*
|
2012-02-17 |
2014-12-10 |
效思因公司 |
热敏纳米颗粒制剂及其制备方法
|
|
US20150037334A1
(en)
|
2012-03-01 |
2015-02-05 |
Amgen Research (Munich) Gmbh |
Long life polypeptide binding molecules
|
|
SG10201610402VA
(en)
|
2012-03-16 |
2017-02-27 |
Merck Patent Gmbh |
Aminoacid lipids
|
|
JP6527331B2
(ja)
|
2012-03-16 |
2019-06-05 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
標的指向アミノ酸脂質
|
|
BR112014024017A8
(pt)
|
2012-03-27 |
2017-07-25 |
Genentech Inc |
Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
|
|
SG11201406422TA
(en)
|
2012-04-09 |
2014-11-27 |
Daiichi Sankyo Co Ltd |
Anti-fgfr2 antibody
|
|
MX356749B
(es)
|
2012-04-27 |
2018-06-12 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-homologo 4 de roundabout (robo4).
|
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
|
US9717724B2
(en)
|
2012-06-13 |
2017-08-01 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies
|
|
CN104768972B
(zh)
|
2012-08-14 |
2019-12-06 |
南洋理工大学 |
血管生成素样4抗体及其用在癌症治疗中的方法
|
|
JP6449161B2
(ja)
|
2012-10-05 |
2019-01-09 |
ジェネンテック， インコーポレイテッド |
炎症性腸疾患の診断治療方法
|
|
US9801874B2
(en)
|
2012-11-20 |
2017-10-31 |
Spectrum Pharmaceuticals |
Method for the preparation of liposome encapsulated vincristine for therapeutic use
|
|
MX363188B
(es)
|
2012-11-30 |
2019-03-13 |
Hoffmann La Roche |
Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
|
|
US9913901B2
(en)
|
2012-12-03 |
2018-03-13 |
Merrimack Pharmaceuticals, Inc. |
Combination therapy for treating HER2-positive cancers
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
US9920121B2
(en)
|
2013-01-25 |
2018-03-20 |
Amgen Inc. |
Antibodies targeting CDH19 for melanoma
|
|
US11156608B2
(en)
|
2013-03-15 |
2021-10-26 |
The Trustees Of The University Of Pennsylvania |
Method for the site-specific covalent cross-linking of antibodies to surfaces
|
|
EP2970446A1
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Research (Munich) GmbH |
Antibody constructs for influenza m2 and cd3
|
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res Munich Gmbh |
Moléculas de unión para bcma y cd3
|
|
ES2753950T3
(es)
|
2013-03-15 |
2020-04-15 |
Amgen Res Munich Gmbh |
Moléculas de unión monocatenarias que comprenden ABP del extremo N
|
|
JP6615745B2
(ja)
|
2013-03-27 |
2019-12-04 |
ジェネンテック， インコーポレイテッド |
ベータ７インテグリンアンタゴニストによる胃腸炎症障害の治療を評価するためのバイオマーカーの使用
|
|
SG11201509618QA
(en)
|
2013-05-24 |
2015-12-30 |
Medimmune Llc |
Anti-b7-h5 antibodies and their uses
|
|
CN105358573B
(zh)
|
2013-05-31 |
2020-10-30 |
基因泰克公司 |
抗壁磷壁酸抗体和缀合物
|
|
CA2913011A1
(en)
|
2013-05-31 |
2014-12-04 |
Genentech, Inc. |
Anti-wall teichoic antibodies and conjugates
|
|
SG11201601044XA
(en)
|
2013-08-12 |
2016-03-30 |
Genentech Inc |
Compositions and method for treating complement-associated conditions
|
|
TWI688401B
(zh)
|
2013-09-13 |
2020-03-21 |
美商安進公司 |
用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
|
|
ES2768618T3
(es)
|
2013-10-08 |
2020-06-23 |
Daiichi Sankyo Co Ltd |
Combinación de anticuerpo anti-FGFR2 y otro agente
|
|
AU2015235986B2
(en)
|
2014-03-27 |
2020-12-03 |
Genentech, Inc. |
Methods for diagnosing and treating inflammatory bowel disease
|
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
EP3174901B1
(en)
|
2014-07-31 |
2019-06-26 |
Amgen Research (Munich) GmbH |
Optimized cross-species specific bispecific single chain antibody constructs
|
|
US20160045596A1
(en)
|
2014-08-05 |
2016-02-18 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
|
|
RU2731055C2
(ru)
|
2014-12-03 |
2020-08-28 |
Дженентек, Инк. |
Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
|
|
EP3226908A1
(en)
|
2014-12-03 |
2017-10-11 |
F.Hoffmann-La Roche Ag |
Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
|
|
WO2016123329A2
(en)
|
2015-01-28 |
2016-08-04 |
Genentech, Inc. |
Gene expression markers and treatment of multiple sclerosis
|
|
PL3653221T3
(pl)
|
2015-02-19 |
2022-12-19 |
Compugen Ltd. |
Przeciwciała anty-pvrig i sposoby ich zastosowania
|
|
WO2016134335A2
(en)
|
2015-02-19 |
2016-08-25 |
Compugen Ltd. |
Pvrig polypeptides and methods of treatment
|
|
WO2016138207A1
(en)
|
2015-02-26 |
2016-09-01 |
Genentech, Inc. |
Integrin beta7 antagonists and methods of treating crohn's disease
|
|
JP6907124B2
(ja)
|
2015-04-17 |
2021-07-21 |
アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ |
Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物
|
|
CA3024195A1
(en)
|
2015-05-12 |
2016-11-17 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for making antibody conjugates
|
|
US11318131B2
(en)
|
2015-05-18 |
2022-05-03 |
Ipsen Biopharm Ltd. |
Nanoliposomal irinotecan for use in treating small cell lung cancer
|
|
ES2810700T3
(es)
|
2015-05-29 |
2021-03-09 |
Hoffmann La Roche |
Metilación del promotor de PD-L1 en cáncer
|
|
EP3322733B1
(en)
|
2015-07-13 |
2021-09-15 |
Compugen Ltd. |
Hide1 compositions and methods
|
|
TWI678213B
(zh)
|
2015-07-22 |
2019-12-01 |
美商史倍壯製藥公司 |
用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究（慕尼黑）公司 |
Dll3及cd3抗體構築體
|
|
EP3337467B1
(en)
|
2015-08-20 |
2020-12-09 |
Ipsen Biopharm Ltd. |
Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
|
|
TW202126293A
(zh)
|
2015-08-21 |
2021-07-16 |
英商益普生生物製藥有限公司 |
使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
|
|
HRP20250052T1
(hr)
|
2015-10-06 |
2025-03-14 |
F. Hoffmann - La Roche Ag |
Postupak liječenja multiple skleroze
|
|
CA3001467A1
(en)
|
2015-10-16 |
2017-04-20 |
Ipsen Biopharm Ltd. |
Stabilizing camptothecin pharmaceutical compositions
|
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
|
KR102815803B1
(ko)
|
2015-12-02 |
2025-06-05 |
주식회사 에스티사이언스 |
당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
|
|
EP3383911B1
(en)
|
2015-12-02 |
2021-01-20 |
STCube & Co. Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
|
JOP20170017B1
(ar)
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
|
|
KR102688969B1
(ko)
|
2016-02-03 |
2024-07-30 |
암젠 리서치 (뮌헨) 게엠베하 |
Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
|
|
WO2017134158A1
(en)
|
2016-02-03 |
2017-08-10 |
Amgen Research (Munich) Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs
|
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
|
JP7148504B2
(ja)
|
2016-06-08 |
2022-10-05 |
ゼンコー，インコーポレイティド |
ＣＤ３２Ｂに交差結合した抗ＣＤ１９抗体を用いたＩｇＧ４関連疾患の治療
|
|
US20200148750A1
(en)
|
2016-07-21 |
2020-05-14 |
Emory University |
Ebola Virus Antibodies and Binding Agents Derived Therefrom
|
|
EP3512564B1
(en)
|
2016-09-14 |
2024-01-17 |
The Trustees of The University of Pennsylvania |
Proximity-based sortase-mediated protein purification and ligation
|
|
WO2018070390A1
(ja)
|
2016-10-12 |
2018-04-19 |
第一三共株式会社 |
抗ｒｏｂｏ４抗体と他剤を含む組成物
|
|
JP2019533684A
(ja)
|
2016-11-02 |
2019-11-21 |
イプセン バイオファーム リミティド |
リポソームイリノテカン、オキサリプラチン、５−フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置
|
|
DK3561057T3
(da)
|
2016-12-22 |
2025-10-27 |
Daiichi Sankyo Co Ltd |
Anti-cd3-antistof og molekyle indeholdende nævnte antistof
|
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
|
TW201837174A
(zh)
|
2017-02-07 |
2018-10-16 |
日商第一三共股份有限公司 |
抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子
|
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
|
TWI782000B
(zh)
|
2017-03-30 |
2022-11-01 |
日商第一三共股份有限公司 |
抗ｇｐｒ２０抗體、其製造方法及其應用
|
|
EP3615569A1
(en)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
|
IL270239B2
(en)
|
2017-05-05 |
2025-01-01 |
Amgen Inc |
Pharmaceutical composition containing bispecific antibody constructs for improved storage and delivery
|
|
CN110753703B
(zh)
|
2017-05-23 |
2024-04-09 |
德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） |
新的cd73抗体、其制备和用途
|
|
KR20250139417A
(ko)
|
2017-05-31 |
2025-09-23 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
|
KR20200015602A
(ko)
|
2017-05-31 |
2020-02-12 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
|
|
KR20200026209A
(ko)
|
2017-06-06 |
2020-03-10 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
|
CN111094334A
(zh)
|
2017-07-19 |
2020-05-01 |
美国卫生与公众服务部 |
用于诊断和治疗乙肝病毒感染的抗体和方法
|
|
KR102818021B1
(ko)
|
2017-10-05 |
2025-06-10 |
다이이찌 산쿄 가부시키가이샤 |
세포 상해성 t 세포 고갈용 조성물
|
|
AR113491A1
(es)
|
2017-12-11 |
2020-05-06 |
Amgen Inc |
Proceso de elaboración continuo para productos de anticuerpos biespecíficos
|
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
|
|
EP3774925A1
(en)
|
2018-04-13 |
2021-02-17 |
Institut national de la santé et de la recherche médicale (INSERM) |
Fc-engineered anti-human ige antibodies and methods of use
|
|
WO2019213416A1
(en)
|
2018-05-02 |
2019-11-07 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
|
JP7599412B2
(ja)
*
|
2018-05-15 |
2024-12-13 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
病原体防除組成物及びその使用
|
|
JP7644706B2
(ja)
|
2018-10-11 |
2025-03-12 |
アムジエン・インコーポレーテツド |
二重特異性抗体コンストラクトの下流プロセシング
|
|
CN113382719B
(zh)
|
2018-12-11 |
2023-10-31 |
迪斯拉普申实验室公司 |
用于递送治疗剂的组合物及其使用方法和制备方法
|
|
EP3983520A1
(en)
|
2019-06-13 |
2022-04-20 |
Amgen, Inc |
Automated biomass-based perfusion control in the manufacturing of biologics
|
|
US20220411511A1
(en)
|
2019-09-26 |
2022-12-29 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
|
KR20220088438A
(ko)
|
2019-10-09 |
2022-06-27 |
주식회사 에스티큐브앤컴퍼니 |
글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
|
|
WO2021097344A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
|
AU2021240028A1
(en)
|
2020-03-19 |
2022-09-15 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
|
US20240262907A1
(en)
|
2020-10-06 |
2024-08-08 |
Xencor, Inc. |
Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
|
|
CN116323671A
(zh)
|
2020-11-06 |
2023-06-23 |
安进公司 |
具有增加的选择性的多靶向性双特异性抗原结合分子
|
|
PH12023500022A1
(en)
|
2021-03-29 |
2024-03-11 |
Daiichi Sankyo Co Ltd |
Stable multispecific molecule and use thereof
|
|
CA3217180A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
|
WO2022245859A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
|
WO2022245877A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
|
EP4410277A4
(en)
*
|
2021-09-30 |
2025-10-22 |
Nof Corp |
LIPID NANOPARTICLES WITH CELLULAR DIRECTIONALITY
|
|
IL316597A
(en)
|
2022-05-12 |
2024-12-01 |
Amgen Res Munich Gmbh |
Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
|
|
CA3265385A1
(en)
|
2022-08-22 |
2024-02-29 |
Abdera Therapeutics Inc |
DLL3 BINDING MOLECULES AND THEIR USES
|
|
TW202421650A
(zh)
|
2022-09-14 |
2024-06-01 |
美商安進公司 |
雙特異性分子穩定組成物
|
|
AU2024302269A1
(en)
|
2023-06-14 |
2025-11-13 |
Amgen Inc. |
T cell engager masking molecules
|